How to appeal a Kaiser Permanente solid-organ transplant denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Kaiser Permanente-specific note: Integrated delivery system — care + insurance coordinated. California DMHC oversight is unique. CA IMR (Independent Medical Review) is a powerful external review track for Kaiser denials.

What Kaiser Permanente's policy requires for solid-organ transplant

Cited policy: Kaiser Permanente Everolimus (Zortress) Coverage for Kidney + Liver + Heart Transplant

FDA-approved indications: (1) kidney transplant maintenance with reduced-dose CNI + basiliximab induction + steroids (Apr 2010); (2) liver transplant maintenance >=30 days post-tx with reduced tac + steroids (Oct 2013); (3) heart transplant maintenance (2018). Trough target 3-8 ng/mL. Not interchangeable with sirolimus.

How Kaiser Permanente denies solid-organ transplant — and how to counter it

Where Kaiser Permanente pushes back: 1) Use sirolimus instead (cheaper, similar mechanism); 2) Step therapy: must fail tacrolimus or MMF first; 3) Dual mTOR + CNI not necessary.

Counter-arguments that hold up: Everolimus FDA-approved Apr 2010 kidney as ALTERNATIVE to MPA in CNI-minimization regimen — label does NOT require MPA failure. A2309 (Tedesco-Silva AJT 2010) + TRANSFORM (Pascual JASN 2018) — everolimus + reduced tacrolimus non-inferior to MMF + standard tacrolimus with lower CMV + BK rates. Sirolimus and everolimus differ in PK (everolimus shorter half-life, twice-daily) + label-specific kidney/liver/heart indications. For BK viremia or CMV-prone recipients everolimus + reduced CNI is preferred over MMF + standard CNI (Brennan AJT 2017). Document specific clinical rationale (BK / CMV / malignancy / CNI-toxicity).

What Kaiser Permanente typically denies for solid-organ transplant

Across Kaiser Permanente's commercial and Medicare books, denials cluster around a small number of patterns. For solid-organ transplant, expect:

• Out-of-network non-emergency denials
• Specialty referrals delayed
• Mental health access (DMHC complaints common)

Treatments most often denied in this category

These are the solid-organ transplant treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Basiliximab (Simulect)
• rATG (Thymoglobulin)
• Alemtuzumab (Campath)
• Tacrolimus IR (Prograf)
• Tacrolimus ER (Astagraf-XL)
• Tacrolimus ER (Envarsus-XR)

How to submit the appeal to Kaiser Permanente

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Kaiser Permanente cited in the denial.
3. File the appeal through Kaiser Permanente's portal (members: https://my.kaiserpermanente.org ; providers: https://providers.kaiserpermanente.org). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In California, file through DMHC for HMOs or CDI for PPOs.

Clinician or prior-auth team handling this on the practice side? See Kaiser Permanente's prior-authorization criteria by drug: Kaiser Permanente PA criteria on ApprovalHelp.